/BFRI
BFRI Stock - Biofrontera Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$0.77+0.72%
+$0.01 (+0.72%) • Dec 19
60
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.23
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.97
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.84
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BFRI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.76 – $0.77
TARGET (TP)$0.88
STOP LOSS$0.70
RISK/REWARD1:1.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.58
52W High$1.87
52W Low$0.54
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $37.30M | $34.07M | $28.67M | $24.10M | $18.85M |
| Gross Profit | $18.70M | $16.63M | $13.49M | $11.36M | $9.78M |
| Gross Margin | 50.1% | 48.8% | 47.0% | 47.1% | 51.9% |
| Operating Income | $-17,210,000 | $-22,677,000 | $-18,581,000 | $-25,201,000 | $-9,606,000 |
| Net Income | $-17,759,000 | $-20,131,000 | $-640,000 | $-37,713,000 | $-10,987,000 |
| Net Margin | -47.6% | -59.1% | -2.2% | -156.5% | -58.3% |
| EPS | $-3.22 | $-13.02 | $-0.61 | $-44.10 | $-18.94 |
Company Overview
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
BFRIBeat Rate
29%
Last 17 quarters
Avg Surprise
-721.2%
EPS vs Estimate
Beats / Misses
5/11
1 met exactly
Latest EPS
$-0.59
Q4 2025
EPS Surprise History
Q1 24
-95.8%
$-2.33vs$-1.19
Q2 24
-13.5%
$-1.85vs$-1.63
Q3 24
+5.9%
$-1.12vs$-1.19
Q4 24
-17.8%
$-0.86vs$-0.73
Q1 25
-11750.0%
$-2.33vs$0.02
Q2 25
-235.7%
$-0.47vs$-0.14
Q3 25
-26.7%
$-0.57vs$-0.45
Q4 25
+1.7%
$-0.59vs$-0.60
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | $0.20 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.60 | $-0.59 | +1.7% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-0.45 | $-0.57 | -26.7% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-0.14 | $-0.47 | -235.7% | ✗ MISS |
Q1 2025 | Mar 21, 2025 | $0.02 | $-2.33 | -11750.0% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.73 | $-0.86 | -17.8% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-1.19 | $-1.12 | +5.9% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-1.63 | $-1.85 | -13.5% | ✗ MISS |
Q1 2024 | Mar 15, 2024 | $-1.19 | $-2.33 | -95.8% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-4.23 | $-4.64 | -9.7% | ✗ MISS |
Q3 2023 | Aug 11, 2023 | $-5.14 | $-6.14 | -19.5% | ✗ MISS |
Q2 2023 | May 12, 2023 | $-4.40 | $-4.40 | 0.0% | = MET |
Q1 2023 | Mar 13, 2023 | $-2.60 | $-2.80 | -7.7% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-6.40 | $-4.60 | +28.1% | ✓ BEAT |
Q3 2022 | Aug 12, 2022 | $-6.20 | $-8.80 | -41.9% | ✗ MISS |
Q2 2022 | May 13, 2022 | $-2.80 | $-1.60 | +42.9% | ✓ BEAT |
Q2 2022 | Apr 8, 2022 | $-3.60 | $-8.40 | -133.3% | ✗ MISS |
Q4 2021 | Nov 30, 2021 | $-11.60 | $-10.20 | +12.1% | ✓ BEAT |
Q4 2021 | Nov 1, 2021 | — | $-0.01 | — | — |
Latest News
Loading news...
Frequently Asked Questions about BFRI
What is BFRI's current stock price?
Biofrontera Inc. (BFRI) is currently trading at $0.77 per share. The stock has moved +0.72% today.
What is the analyst price target for BFRI?
No analyst price targets are currently available for this stock.
What sector is Biofrontera Inc. in?
Biofrontera Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is BFRI's market cap?
Biofrontera Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does BFRI pay dividends?
No, Biofrontera Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAYTU
Aytu BioPharma, Inc.
$2.55
Mkt Cap: $0.0B
COCP
Cocrystal Pharma, Inc.
$0.99
Mkt Cap: $0.0B
DWTX
Dogwood Therapeutics, Inc.
$6.45
Mkt Cap: $0.0B
EVGN
Evogene Ltd.
$1.02
Mkt Cap: $0.0B
GELS
Gelteq Limited Ordinary Shares
$0.90
Mkt Cap: $0.0B
IMNN
Imunon, Inc.
$3.75
Mkt Cap: $0.0B
PRPH
ProPhase Labs, Inc.
$0.09
Mkt Cap: $0.0B
SBFM
Sunshine Biopharma, Inc.
$1.39
Mkt Cap: $0.0B
SNSE
Sensei Biotherapeutics, Inc.
$8.86
Mkt Cap: $0.0B
TRIB
Trinity Biotech plc
$0.90
Mkt Cap: $0.0B
Explore stocks similar to BFRI for comparison